Sermorelin-Specific Considerations Sermorelins contraindications mirror those of any GH-pathway intervention: active malignancy, pregnancy, breastfeeding, severe pituitary disease, uncontrolled diabetes
Currently, there is limited evidence on the safety and efficacy of intermittent dosing strategies, and the consensus among obesity specialists is that this approach is not generally advised except in specific clinical scenarios under close supervision
Kushwaha R, Li Y, Makarava N, Pandit NP, Molesworth K, Birukov KG, et al
Understand the Risks: Medical testing and the appropriate dosage can mitigate the risks associated with antioxidant use
The GLP-1, GIP, and glucagon mechanism is complex